The deal will see the Singapore-based social technology company list on the Nasdaq, valuing the combined entity at approximately $300 million.
The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.
Predictive Discovery and Robex Resources merge, creating a mid-tier producer targeting over 400,000 ounces of gold annually.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
Applied Materials forecasts a $600 million revenue hit, signaling broader disruption for the global chip industry amid escalating US-China tech tensions.
Strategic acquisition aims to bolster Firefly's national security and defense capabilities, expanding its space and defense mission services.